| Autor: |
Gorodnova TV; Department of Gynecology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia. t.gorodnova@mail.ru., Sokolenko AP; Department of Tumor Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia., Kuligina E; Department of Tumor Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia., Berlev IV; Department of Gynecology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia., Imyanitov EN; Department of Tumor Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia. |
| Abstrakt: |
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages. Cytoreductive surgery is a backbone of EOC treatment. Wherever possible, EOC patients are subjected to primary debulking surgery (PDS) with the aim to remove all visible tumor lumps. Some patients cannot undergo PDS due to extensive disease spread and/or high risk of perioperative morbidity, therefore they are subjected to neoadjuvant chemotherapy (NACT) before the surgery. Therapy given before surgery or as adjuvant treatment usually consists of combination of carboplatin and paclitaxel. Gemcitabine, topotecan, pegylated liposomal doxorubicin and poly ADP ribose polymerase inhibitors (PARPi) are commonly used for the management of EOC relapses. Consideration of BRCA1/2 germ-line and somatic status is getting increasingly important for the proper treatment planning. |
